Use of androgen deprivation therapy in prostate cancer: indications and prevalence

Roisín M. Connolly(Johns Hopkins University), Emmanuel S. Antonarakis(Johns Hopkins University)

Asian Journal of Andrology

January 9, 2012

10.1038/aja.2011.103

Cited by 63

Related Papers

An immunohistochemical signature comprising PTEN, MYC, and Ki67 predicts progression in prostate cancer patients receiving adjuvant docetaxel after prostatectomy

|Cancer|2012|107

Entinostat, nivolumab and ipilimumab for women with advanced HER2-negative breast cancer: a phase Ib trial

|Nature Cancer|2024|46

Phase I Study of Entinostat and Nivolumab with or without Ipilimumab in Advanced Solid Tumors (ETCTN-9844)

|Clinical Cancer Research|2021|35